XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $405K invested in XTL Biopharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more ownership
Funds ownership: 0.49% → 0.49% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
16% less capital invested
Capital invested by funds: $483K → $405K (-$77.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$1.32K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$794 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
-$1.32K |
XTLB Hedge Fund Activity: Q2 2014 in Review
5 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2014, worth a combined $405K — down 16% from $483K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was B. Riley Wealth Advisors, opening a new position worth an estimated $1.32K. The largest seller was UBS, cutting an estimated $1.32K.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2014, up from 4 in Q1 2014.
- Funds reported $405K of XTL Biopharmaceuticals stock for Q2 2014, down 16% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q2 2014 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q2 2014 was B. Riley Wealth Advisors, an estimated $1.32K added.
- The largest XTL Biopharmaceuticals seller in Q2 2014 was UBS, an estimated $1.32K sold.
Based on aggregated 13F filings for Q2 2014.